Clarity Pharmaceuticals Ltd

ASX:CU6.AX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🩺 Medical Instruments

💊 Pharmaceuticals

Location

Australia

Market Cap

USD 425.55 M

Share Price

USD 1.32

Avg Daily Volume

2,911,372

Change (1 day)

-7.26%

Change (1 year)

-58.98%

Change (YTD)

-48.69%

Clarity Pharmaceuticals Ltd Share Price Year-To-Date (YTD) return on June 20, 2025: -48.69%

Clarity Pharmaceuticals Ltd Share Price Year-To-Date (YTD) return is -48.69% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Clarity Pharmaceuticals Ltd 52-week low Share Price is USD 6.02 on June 20, 2025, which is 354.40% above the current Share Price.
Clarity Pharmaceuticals Ltd 52-week low Share Price is USD 0.90 on June 20, 2025, which is -32.18% below the current Share Price.
Clarity Pharmaceuticals Ltd average Share Price for the last 52 weeks is USD 3.11.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

ASX: CU6.AX

Clarity Pharmaceuticals Ltd

CEO	Ms. Michelle Parker
IPO Date	Aug. 25, 2021
Location	Australia
Headquarters	National Innovation Centre
Employees	50
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🩺 Medical Instruments 💊 Pharmaceuticals

Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.